Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD and PD-1 in Second-line Metastatic Muscle Invasive Bladder Cancer
NCT04101812Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Sep 2019
- Primary completion
- May 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in muscle-invasive bladder cancer (MIBC), sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04101812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101812.